Retinoid target genes in acute promyelocytic leukemia
نویسندگان
چکیده
منابع مشابه
CCAAT/enhancer binding protein ε is a potential retinoid target gene in acute promyelocytic leukemia treatment
Evidence from studies of both normal and leukemic cells suggests that myeloid hematopoiesis is a multistage developmental process requiring coordinate expression of multiple genes by various lineage-restricted transcription factors. Consequently, myeloid-specific transcription factors play a critical role in myelopoiesis, and the failure to induce these transcription factors in a timely fashion...
متن کاملTarget acquisition and acute promyelocytic leukemia.
promyelocytic leukemia (APL) is characterized by a variety of chromoso-mal translocations into the retinoic acid receptor-α (RARα) gene. The first of these cloned was t(15;17), a transloca-tion that results in fusion of the PML gene with RARα. This translocation is also the most prevalent, found in 95% of APL cases. Other translocations associated with fusion proteins in variant APLs were subse...
متن کاملRetinoid differentiation therapy in promyelocytic leukemia.
Acute promyelocytic leukemia (APL) is a specific type of acute myeloid leukemia characterized by the morphology of the blast cells, a specific t(15;17) translocation, and risks of definite coagulopathy. Recently this leukemia was further characterized by an exquisite sensitivity to all-trans retinoic acid's differentiation effect and the production of a fusion gene altering the gene of RARalpha...
متن کاملAcute promyelocytic leukemia: a model of molecular target based therapy.
Leukemia, a group of hematological malignancies characterized by clonal expansion of hematopoietic cells with uncontrolled proliferation, decreased apoptosis and blocked differentiation, is one of the most notorious enemies of mankind which accounts for some 300,000 new cases and 222,000 deaths each year worldwide. Leukemia can be divided into acute or chronic, lymphoid or myeloid types, based ...
متن کاملAcute myeloid leukemia and acute promyelocytic leukemia.
The therapeutic approach to the patient with acute myeloid leukemia (AML) currently evolves toward new frontiers. This is particularly apparent from the entree of high-throughput diagnostic technologies and the identification of prognostic and therapeutic targets, the introduction of therapies in genetically defined subgroups of AML, as well as the influx of investigational approaches and novel...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia
سال: 2003
ISSN: 0887-6924,1476-5551
DOI: 10.1038/sj.leu.2403065